[ad_1]
Join us on Monday, October 3 for a virtual discussion with WIRED’s deputy global editorial director, Greg Williams and Professor Yaakov Nahmias, founder of Tissue Dynamics, who will explore the future of drug development and how they are dramatically increasing clinical success rates by using sensor-driven discovery.
It costs an estimated $2.6B to bring a single molecule to market, of which 90 percent fail clinical studies. And we don’t know why. This is a huge problem for drug developers, as no new learnings can be extracted from failed studies—a problem Tissue Dynamics is committed to solving.
By using a human-relevant model (as opposed to animals) and integrated sensors within microscopic living tissues, users can communicate with tissues as well as receive and send information in a way that wasn’t possible before. This is dramatically increasing clinical success rates.
During this virtual briefing, Prof. Nahmias will discuss the impact of sensor-driven AI within the pharmaceutical industry. Register today.
About Prof. Yaakov Nahmias
Prof. Yaakov “Koby” Nahmias is a bioengineer and innovator, whose breakthroughs ranged from the first 3D printing of cells to the first commercial human-on-chip technology.
About WIRED Briefings
Designed as an extension of WIRED’s long-running live conference portfolio, WIRED Briefings are punchy, deliberate and engaging sessions that reflect the same high calibre of speakers and programming featured at a WIRED event. Part of the WIRED Foresight series, curated by WIRED deputy global editorial director, Greg Williams.
[ad_2]
Source link
